Evidence map›Paper›PMID 38022536›Full record

ArticleFrontiers in immunology2023

A prognostic signature based on snoRNA predicts the overall survival of lower-grade glioma patients.

Yi Zhou, Wen Yin, Yirui Kuang, Zhaoping Wu, Haoxuan Huang, Weidong Liu, Xingjun Jiang, Caiping Ren

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Selective remodeling of snoRNA and sdRNA biology in glioblastoma.Frontiers in cell and developmental biology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yi ZhouDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wen YinDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yirui KuangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhaoping WuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Haoxuan HuangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Weidong LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xingjun JiangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Caiping RenDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiangya Hospital Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Small nucleolar RNAs (snoRNAs) are a group of non-coding RNAs enriched in the nucleus which direct post-transcriptional modifications of rRNAs, snRNAs and other molecules. Recent studies have suggested that snoRNAs have a significant role in tumor oncogenesis and can be served as prognostic markers for predicting the overall survival of tumor patients. Methods: We screened 122 survival-related snoRNAs from public databases and eventually selected 7 snoRNAs that were most relevant to the prognosis of lower-grade glioma (LGG) patients for the establishment of the 7-snoRNA prognostic signature. Further, we combined clinical characteristics related to the prognosis of glioma patients and the 7-snoRNA prognostic signature to construct a nomogram. Results: The prognostic model displayed greater predictive power in both validation set and stratification analysis. Results of enrichment analysis revealed that these snoRNAs mainly participated in the post-transcriptional process such as RNA splicing, metabolism and modifications. In addition, 7-snoRNA prognostic signature were positively correlated with immune scores and expression levels of multiple immune checkpoint molecules, which can be used as potential biomarkers for immunotherapy prediction. From the results of bioinformatics analysis, we inferred that SNORD88C has a major role in the development of glioma, and then performed in vitro experiments to validate it. The results revealed that SNORD88C could promote the proliferation, invasion and migration of glioma cells. Discussion: We established a 7-snoRNA prognostic signature and nomogram that can be applied to evaluate the survival of LGG patients with good sensitivity and specificity. In addition, SNORD88C could promote the proliferation, migration and invasion of glioma cells and is involved in a variety of biological processes related to DNA and RNA.

Indexed as

GliomaRNA, Small NucleolarComputational BiologyHumansPrognosisRNA, Small Nucleolarinteraction networklower-grade gliomaoverall survivalprognostic signaturesnoRNA

Identifiers

PMID38022536
PMCPMC10646524
OpenAlexW4388126401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.